Investor Relations

Webcast ImageWebcast
Q4 2017 Nuvectra Earnings Conference Call (Live)
03/06/18 at 4:30 p.m. ET
Q4 2017 Nuvectra Earnings Conference Call
Tuesday, March 6, 2018 4:30 p.m. ET  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate ProfileNuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge, neural-interface technologies for the neuroscience pre-clinical research market.

On March 14, 2016, Nuvectra Corporation completed its spin-off from Greatbatch, Inc. into an independent, publicly-traded neurostimulation medical device company. The company is headquartered in Plano, Texas, with additional locations in Denver, Ann Arbor, and Minneapolis.

Nuvectra currently trades on the NASDAQ Global Market (NASDAQ) under the ticker symbol "NVTR."


Stock Quote NVTR (Common Stock) $10.20 + 0.15 (1.49%)
ExchangeNASDAQ
Volume11,512
Today's Open$10.17
Previous Close$10.05
Data as of 02/23/18 4:00 p.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NVTR.O.  Currently trading at $10.20 with a 52 week high of $15.00 and a 52 week low of $5.76.

Recent News

February 22, 2018

Nuvectra™ to Report Fourth Quarter and Full Year 2017 Financial Results on March 6, 2018

PLANO, Texas, Feb. 22, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it will release its financial results for the fourth quarter and full year ended December 31, 2017 on Tuesday, March 6, 2018 after market close. Nuvectra will hold a conference call on Tuesday, March 6, 2018, at 4:30pm ET to discuss the results. The dial-in numbers are (844) 882-7830 for domestic callers and (574) 990-9704 for international call

Read More >

February 20, 2018

Nuvectra Secures $45 Million Second Amendment to Existing Loan and Security Agreement

Agreement Provides Company with Increased Financial Flexibility and Extended Amortization Period PLANO, Texas, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that it has reached an agreement with Silicon Valley Bank and Oxford Finance, the lenders of its existing credit facility, to secure a second amendment to the Company’s loan and security agreement for $45.0 million. On February 16, 2018, the Company amende

Read More >


Investor Contact

The Ruth Group
Brian Johnston
Tram Bui
investors@nuvectramed.com

Events
DateTitle
03/06/18 4:30 p.m. ET
Q4 2017 Nuvectra Earnings Conference Call